Reducing Chemotherapy-Induced DNA Damage via nAChR-Mediated Redox Reprograming—A New Mechanism for SCLC Chemoresistance Boosted by Nicotine
Up to 60% of patients with small cell lung cancer (SCLC) continue to smoke, which is associated with worse clinical outcomes. Platinum-based chemotherapies, in combination with topoisomerase inhibitors, are first-line therapies for SCLC, with rapid chemoresistance as a major barrier. We provided evi...
Main Authors: | Bian, T. (Author), Fujioka, N. (Author), Huo, Z. (Author), Jiang, Y. (Author), Jin, L. (Author), Kaye, F.J (Author), Salloum, R.G (Author), Song, L. (Author), Wang, Y. (Author), Warren, G.W (Author), Xing, C. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Pathology and Classification of SCLC
by: Maria Gabriela Raso, et al.
Published: (2021-02-01) -
Tracheal polypoid combined small cell lung cancer (C‐SCLC): A case report
by: Alberto Testori, et al.
Published: (2021-07-01) -
Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC
by: Jiarong Bao, et al.
Published: (2019-05-01) -
Metabolic Reprogramming of Chemoresistant Cancer Cells and the Potential Significance of Metabolic Regulation in the Reversal of Cancer Chemoresistance
by: Xun Chen, et al.
Published: (2020-07-01) -
Effect of genetic variation in Notch regulator DTX1 on SCLC prognosis compared with the effect on NSCLC prongosis
by: Seung Soo Yoo, et al.
Published: (2020-09-01)